With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk A/S Dữ liệu về giá theo thời gian thực
The current price of Novo Nordisk A/S in the market is 1.078.078,59 ₫, with a 24-hour trading volume of 15,9T ₫. The asset's market cap is 4,78P ₫, after moving 0.07% in the last day.
Tokenized Novo Nordisk A/S is trading at 1.094.589,71 ₫, with a tokenized market cap of 88,26B ₫ and a 24-hour trading volume of 23,4B ₫. The tokenized asset has moved 1.34% in the past 24 hours.